MRD Clinical Trials

13 recruitingLast updated: June 17, 2026

There are 13 actively recruiting mrd clinical trials across 4 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 4. Top locations include Suzhou, Jiangsu, China, Shanghai, China, Changchun, Jilin, China. Updated daily from ClinicalTrials.gov.


MRD Trials at a Glance

13 actively recruiting trials for mrd are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Suzhou, Shanghai, and Changchun. Lead sponsors running mrd studies include Guangdong Association of Clinical Trials, Hospital Universitario Dr. Jose E. Gonzalez, and Fudan University.

Browse mrd trials by phase

Treatments under study

About MRD Clinical Trials

Looking for clinical trials for MRD? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MRD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MRD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Not Applicable

RGL-305+ Lymphoma + Exploratory Clinical Study

Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Fudan University12 enrolled1 locationNCT07006012
Recruiting
Phase 3

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

B-ALLMRD-positiveAllogenetic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital70 enrolled1 locationNCT07441291
Recruiting
Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple MyelomaPost-transplant MRD-guided Maintenance TherapyPre-transplant Purging
M.D. Anderson Cancer Center40 enrolled1 locationNCT06207799
Recruiting
Phase 2

Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

ALLMRD-positiveHematopoietic Stem Cell Transplantation
Sheng-Li Xue, MD42 enrolled1 locationNCT05940961
Recruiting
Phase 2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+25 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Recruiting
Phase 4

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

MRDMultiple MyelomaHigh-Risk+1 more
The First Affiliated Hospital of Soochow University59 enrolled1 locationNCT06409702
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Multiple Endocrine Neoplasia Type 1Multiple Endocrine Neoplasia Type 2Rare Disorders+337 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting

Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer

Breast CancerMRD
The First Hospital of Jilin University40 enrolled1 locationNCT06918262
Recruiting
Phase 2

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Acute Lymphoblastic LeukemiaMeasurable Residual Disease (MRD)
Hospital Universitario Dr. Jose E. Gonzalez30 enrolled1 locationNCT06886074
Recruiting

The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.

Clinical Complete Response Rate With Negative MRD
Yunnan Cancer Hospital22 enrolled1 locationNCT06477991
Recruiting
Phase 2

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

MRDAML
Shanghai Tong Ren Hospital58 enrolled4 locationsNCT05736978
Recruiting
Phase 2

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

MRD
Guangdong Association of Clinical Trials180 enrolled16 locationsNCT05536505